Drug intelligence / Profile preview

PMC2129G12

Development stage: Preclinical
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous (inferred; Typical For mRNA-LNP Therapies)

Overview

PMC2129G12 is an investigational drug candidate utilizing a novel targeted technology based on mRNA-lipid nanoparticle (mRNA-LNP) delivery. It is being explored for the treatment of solid tumors. The mechanism involves delivering messenger RNA encapsulated in lipid nanoparticles to target and modulate gene expression within tumor cells, potentially leading to anti-tumor effects. This approach leverages the ability of mRNA-LNP platforms to induce or suppress specific protein production in cancer cells, representing a new modality in oncology therapeutics[1].

Targets

EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on PMC2129G12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMC2129G12.

Explore the full profile